Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. reported total revenues of $403.1 million for fiscal year 2025, generating a gross profit of $273.9 million (calculated from total revenues of $403.1M minus cost of goods sold of $129.2M). The company achieved income from operations of $60.3 million, but significant interest expense of $84.6M resulted in a net loss of $22.7 million. The balance sheet shows total assets of $465.9 million, with strong current assets of $462.6M including $167.9M in cash and equivalents. However, total liabilities of $767.9M create a stockholders' deficit of $302.0M. Cash flow from operations was negative $13.1M, but financing activities provided $36.2M, resulting in a net cash increase of $23.1M. The company's performance shows operational profitability but remains challenged by debt servicing costs.

Key Takeaways